You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 12, 2025

Suppliers and packagers for generic pharmaceutical drug: mitoxantrone hydrochloride


✉ Email this page to a colleague

« Back to Dashboard


mitoxantrone hydrochloride

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Fresenius Kabi Usa MITOXANTRONE HYDROCHLORIDE mitoxantrone hydrochloride INJECTABLE;INJECTION 077496 ANDA Fresenius Kabi USA, LLC 63323-132-10 1 VIAL, MULTI-DOSE in 1 BOX (63323-132-10) / 10 mL in 1 VIAL, MULTI-DOSE 2006-04-11
Fresenius Kabi Usa MITOXANTRONE HYDROCHLORIDE mitoxantrone hydrochloride INJECTABLE;INJECTION 077496 ANDA Fresenius Kabi USA, LLC 63323-132-12 1 VIAL, MULTI-DOSE in 1 BOX (63323-132-12) / 12.5 mL in 1 VIAL, MULTI-DOSE 2006-04-11
Fresenius Kabi Usa MITOXANTRONE HYDROCHLORIDE mitoxantrone hydrochloride INJECTABLE;INJECTION 077496 ANDA Fresenius Kabi USA, LLC 63323-132-15 1 VIAL, MULTI-DOSE in 1 BOX (63323-132-15) / 15 mL in 1 VIAL, MULTI-DOSE 2006-04-11
Hospira MITOXANTRONE HYDROCHLORIDE mitoxantrone hydrochloride INJECTABLE;INJECTION 076871 ANDA Hospira, Inc. 61703-343-18 1 VIAL, MULTI-DOSE in 1 CARTON (61703-343-18) / 10 mL in 1 VIAL, MULTI-DOSE 2006-04-11
Hospira MITOXANTRONE HYDROCHLORIDE mitoxantrone hydrochloride INJECTABLE;INJECTION 076871 ANDA Hospira, Inc. 61703-343-65 1 VIAL, MULTI-DOSE in 1 CARTON (61703-343-65) / 12.5 mL in 1 VIAL, MULTI-DOSE 2006-04-11
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug: Mitoxantrone Hydrochloride

Last updated: July 28, 2025

Introduction

Mitoxantrone Hydrochloride is a potent anthracenedione antineoplastic agent primarily used in treating various cancers, including advanced breast cancer, prostate cancer, and multiple sclerosis. Its efficacy is well-documented, but sourcing authentic, high-quality Mitoxantrone Hydrochloride remains critical for healthcare providers and pharmaceutical manufacturers. This article explores the landscape of global suppliers, emphasizing quality, regulatory compliance, and market dynamics that influence procurement strategies.

Overview of Mitoxantrone Hydrochloride

Mitoxantrone Hydrochloride functions as an anthracenedione compound that intercalates DNA and inhibits topoisomerase II, leading to cytotoxic effects on rapidly dividing cells. Its clinical utility hinges on strict pharmaceutical standards, including purity (>98%), stability, and bioavailability. The growing demand for such chemotherapeutics has fostered an extensive supply chain, involving both innovator companies and generic manufacturers.

Major Suppliers in the Global Market

1. Sanofi (Sanofi-Aventis)

Sanofi, a global pharmaceutical leader headquartered in France, markets branded Mitoxantrone Hydrochloride under the trade name Novantrone. As the original patent holder, Sanofi maintains a significant share of the authorized supply chain, ensuring high-quality standards, regulatory compliance, and reliable distribution channels. Their formulation adheres to strict cGMP (current Good Manufacturing Practices), ensuring product integrity across markets.

2. Teva Pharmaceuticals

Teva, based in Israel, is a prominent generic drug manufacturer supplying Mitoxantrone Hydrochloride globally. Their offerings meet international quality standards and are often used as a cost-effective alternative in markets with limited access to branded drugs. Teva's extensive manufacturing infrastructure ensures a consistent supply for hospitals and clinics worldwide.

3. Hospira / Pfizer

Hospira, now integrated into Pfizer, supplies a range of chemotherapeutic agents, including Mitoxantrone Hydrochloride. Their manufacturing facilities are FDA-compliant, emphasizing safety and potency. Pfizer's distribution network enhances availability in North America and Europe, with a focus on ensuring compliance with local regulatory agencies.

4. Dr. Reddy’s Laboratories

An Indian multinational, Dr. Reddy’s specializes in generic pharmaceuticals. Their Mitoxantrone Hydrochloride products are widely used in emerging markets, particularly within Asia, Latin America, and Africa. Their adherence to international quality standards and lower price points make them a significant supplier in cost-sensitive markets.

5. Sun Pharmaceutical Industries

As another Indian pharmaceutical giant, Sun Pharma offers Mitoxantrone Hydrochloride that complies with WHO guidelines. The company’s broad distribution network facilitates access to the drug in developing regions, contributing to global cancer treatment efforts.

6. Other Notable Suppliers

  • Stell Pharmatech: A Chinese manufacturer providing affordable generic alternatives, subject to regulatory approval.
  • Lupin Limited: An Indian firm with a growing portfolio of oncology drugs, including Mitoxantrone Hydrochloride.
  • Ebewe Pharma: An Austrian-based company with a focus on oncology injectables, ensuring high standards for quality and safety.

Regional Supplier Considerations

North America and Europe

Suppliers such as Sanofi, Pfizer, and Teva dominate, emphasizing strict regulatory adherence (FDA, EMA) and high manufacturing standards. These regions often prioritize quality assurance, especially for clinical and hospital use.

Asia, Latin America, and Africa

Manufacturers like Dr. Reddy’s, Sun Pharma, and Lupin play a vital role by providing affordable, high-quality generics. Regulatory compliance varies, necessitating due diligence for quality assurance to ensure safety and efficacy.

Emerging Markets and Access Challenges

In developing regions, supply chain disruptions, regulatory hurdles, and affordability influence supplier choice. Local approvals, import tariffs, and infrastructure capacity shape procurement decisions, highlighting the importance of partnerships with reliable local distributors.

Regulatory and Quality Considerations

Reliable suppliers must comply with international standards like cGMP, WHO-GMP, and regional regulations (FDA, EMA, CDSCO). Authentic product sourcing involves verifying batch certificates, Certificates of Analysis (COA), and registration documentation. counterfeit mitigation is vital, as illegal imports and adulterated drugs pose risks to patient safety.

Emerging Trends Influencing Supplier Selection

1. Increasing Generic Competition

The expiry of patents and the rise of generics have expanded available suppliers but also increased market saturation, requiring buyers to vet quality rigorously.

2. Supply Chain Transparency

Enhanced traceability through serialization and blockchain technologies improves supplier reliability, allowing better risk management.

3. Price Optimization

Cost pressures lead healthcare providers to diversify sources without compromising standards. Coordinating with reputable generics producers balances affordability with safety.

4. Digital and E-Procurement Platforms

Platforms like PharmaSupply and EurSafe facilitate streamlined supplier vetting, quality assessments, and procurement processes, expanding access to multiple suppliers worldwide.

Conclusion

Mitoxantrone Hydrochloride's global supply landscape comprises a mix of originator, generic, and regional manufacturers. Ensuring procurement from reputable sources compliant with international standards is essential to maintaining treatment efficacy and patient safety. Strategic partnerships, due diligence, and understanding regional market nuances are vital for healthcare providers and pharmaceutical companies to secure a reliable supply of this critical chemotherapeutic agent.

Key Takeaways

  • Diverse Supplier Base: Major suppliers include Sanofi, Teva, Pfizer, Dr. Reddy’s, and Sun Pharma, offering both brand-name and generic options.
  • Quality and Compliance: Regulatory adherence and transparent quality assurance are non-negotiable factors in supplier selection.
  • Regional Dynamics: Market preferences and regulatory environments impact supplier choice, with developed markets favoring high-standard originators and emerging markets relying heavily on generics.
  • Emerging Technologies: Digital procurement tools and serialization improve supply chain integrity, especially amid growing counterfeit concerns.
  • Market Trends: Patent expirations, price pressures, and global health initiatives continue to shape supplier competitiveness and availability.

FAQs

1. Is Mitoxantrone Hydrochloride available from multiple suppliers globally?
Yes. The drug is supplied by several manufacturers worldwide, including both original innovators like Sanofi and various generic producers like Teva, Dr. Reddy’s, and Sun Pharma.

2. How can buyers verify the authenticity and quality of Mitoxantrone Hydrochloride from suppliers?
Buyers should request Certificates of Analysis, regulatory registration documents, and ensure supplier compliance with cGMP standards. Purchasing through authorized distributors and conducting laboratory testing upon receipt also safeguards quality.

3. Are there regional differences in supplier regulation compliance?
Yes. Suppliers in North America and Europe generally adhere to strict FDA or EMA standards, while those in emerging regions may follow WHO-GMP or local guidelines, necessitating verification for international procurement.

4. What role do online procurement platforms play in sourcing Mitoxantrone Hydrochloride?
Platforms facilitate supplier vetting, streamline procurement, and ensure traceability. They allow buyers to compare multiple suppliers, review compliance credentials, and mitigate supply chain risks.

5. What are the key factors influencing supplier selection for Mitoxantrone Hydrochloride?
Critical factors include product quality, regulatory compliance, supply reliability, price competitiveness, regional approvals, and supply chain transparency.

References

  1. [1] Sanofi Official Site. Novantrone (Mitoxantrone). Accessed 2023.
  2. [2] Teva Pharmaceuticals Official Website. Product Details on Mitoxantrone Hydrochloride. Accessed 2023.
  3. [3] Pfizer / Hospira. Oncology Portfolio. 2022.
  4. [4] World Health Organization. Good Manufacturing Practices (GMP) Guidelines. 2021.
  5. [5] GlobalData. Market Analysis of Oncology Drugs 2022.

This comprehensive overview aims to guide healthcare decision-makers and procurement professionals, emphasizing the importance of high standards and strategic sourcing in securing Mitoxantrone Hydrochloride.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.